Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

UNBELIEVABLE: Incyte s q2 2025 earnings what to expect | History Defined

Incyte Corporation (INCY) is a Wilmington, Delaware–based global biopharmaceutical company focused on developing and marketing innovative therapies in oncology, immunology, dermatology, and inflammation. Founded in 2002, Incyte has grown into a large-cap biotech with a market cap of $13.3 billion.

INCY is all geared up its fiscal Q2 earnings for 2025 before the market opens on Tuesday, Apr. 29. Prior to this event, analysts project this biopharmaceutical company to report a profit of $1.13 per share, up 155.7% from a loss of $2.03 per share in the year-ago quarter. The company has missed Wall Street's bottom-line estimates in three of the last four quarters, while surpassing on one quarter. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.